þ
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
68-0423298
|
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S Employer
Identification No.)
|
Large accelerated filer
|
Accelerated filer
|
Non-accelerated filer
|
Smaller reporting company
|
o
|
o
|
(Do not check if a smaller reporting company) o
|
þ
|
Exhibit
Number
|
Description
|
|
3.1
|
Restated Certificate of Incorporation of Registrant (included as Exhibit 3.1 of the Company’s Annual Report on Form 10-K for the year ended March 31, 2007, and incorporated herein by reference).
|
|
3.2
|
Amended and Restated Bylaws of Registrant, as amended effective on June 11, 2008 (included as Exhibit 3.2 to the Company’s Annual Report on Form 10-K for the year ended March 31, 2008, and incorporated herein by reference).
|
|
4.1
|
Specimen Common Stock Certificate (included as Exhibit 4.1 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
|
4.2
|
Warrant to Purchase Series A Preferred Stock of Registrant by and between Registrant and Venture Lending & Leasing III, Inc., dated April 21, 2004 (included as Exhibit 4.2 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
|
4.3
|
Warrant to Purchase Series B Preferred Stock of Registrant by and between Registrant and Venture Lending & Leasing IV, Inc., dated June 14, 2006 (included as Exhibit 4.3 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
|
4.4
|
Form of Warrant to Purchase Common Stock of Registrant (included as Exhibit 4.4 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
|
4.5
|
Form of Warrant to Purchase Common Stock of Registrant (included as Exhibit 4.5 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
|
4.6
|
Form of Warrant to Purchase Common Stock of Registrant (included as Exhibit 4.11 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
|
4.7
|
Form of Warrant to Purchase Common Stock of Registrant (included as Exhibit 4.12 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
|
4.8
|
Form of Warrant to Purchase Common Stock of Registrant (included as Exhibit 10.3 to the Company’s Current Report on Form 8-K filed August 13, 2007, and incorporated herein by reference).
|
|
4.9
|
Form of Warrant to Purchase Common Stock of Registrant (included as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed March 28, 2008, and incorporated herein by reference).
|
|
4.10
|
Form of Common Stock Purchase Warrant for April 2009 offering (included as Exhibit 4.15 to the Company’s Registration Statement on Form S-1 (File No. 333-158539) declared effective on July 24, 2009, and incorporated herein by reference).
|
|
4.11
|
Warrant issued to Dayl Crow, dated March 4, 2009 (included as Exhibit 4.16 to the Company’s Annual Report on Form 10-K filed on June 11, 2009, and incorporated herein by reference).
|
|
4.12
|
Form of Common Stock Purchase Warrant for July 2009 offering, (included as Exhibit 4.15 to the Company’s Registration Statement on Form S-1 (File No. 333-158539), as amended, declared effective on July 24, 2009, and incorporated herein by reference)
|
|
4.13
|
Warrant to Purchase Shares of Common Stock of Oculus Innovative Sciences, Inc., (Included as Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on May 6, 2010, and incorporated herein by reference).
|
|
10.1
|
Form of Indemnification Agreement between Registrant and its officers and directors (included as Exhibit 10.1 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
10.2
|
Form of 2006 Stock Incentive Plan and related form stock option plan agreements (included as Exhibit 10.6 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
|
10.3
|
Amended and Restated Investors Rights Agreement, effective as of September 14, 2006 (included as Exhibit 4.6 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
|
10.4
|
Form of Promissory Note issued to Venture Lending & Leasing III, Inc. (included as Exhibit 4.7 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
|
10.5
|
Form of Promissory Note (Equipment and Soft Cost Loans) issued to Venture Lending & Leasing IV, Inc. (included as Exhibit 4.8 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
|
10.6
|
Form of Promissory Note (Growth Capital Loans) issued to Venture Lending & Leasing IV, Inc. (included as Exhibit 4.9 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
10.7
|
Form of Promissory Note (Working Capital Loans) issued to Venture Lending & Leasing IV, Inc. (included as Exhibit 4.10 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
|
10.8
|
Office Lease Agreement, dated October 26, 1999, between Registrant and RNM Lakeville, L.P. (included as Exhibit 10.7 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
|
10.9
|
Amendment to Office Lease No. 1, dated September 15, 2000, between Registrant and RNM Lakeville L.P. (included as Exhibit 10.8 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
|
10.10
|
Amendment to Office Lease No. 2, dated July 29, 2005, between Registrant and RNM Lakeville L.P. (included as Exhibit 10.9 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
10.11
|
Amendment No. 3 to Lease, dated August 23, 2006, between Registrant and RNM Lakeville L.P. (included as Exhibit 10.23 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
|
10.12
|
Amendment No. 4 to Lease, dated September 13, 2007, by and between Registrant and RNM Lakeville L.P. (included as Exhibit 10.43 to the Company’s Annual Report on Form 10-K for the year ended March 31, 2008, and incorporated herein by reference).
|
|
10.13
|
Office Lease Agreement, dated May 15, 2005, between Oculus Technologies of Mexico, S.A. de C.V. and Antonio Sergio Arturo Fernandez Valenzuela (translated from Spanish) (included as Exhibit 10.10 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
|
10.14
|
Office Lease Agreement, dated July 2003, between Oculus Innovative Sciences, B.V. and Artikona Holding B.V. (translated from Dutch) (included as Exhibit 10.11 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
10.15
|
Amendment to Office Lease Agreement, effective February 15, 2008, by and between Oculus Innovative Sciences Netherlands B.V. and Artikona Holding B.V. (translated from Dutch) (included as Exhibit 10.44 to the Company’s Annual Report on Form 10-K for the year ended March 31, 2008, and incorporated herein by reference).
|
|
10.16
|
Form of Director Agreement (included as Exhibit 10.20 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
|
10.17
|
Leasing Agreement, dated May 5, 2006, by and between Mr. Jose Alfonzo I. Orozco Perez and Oculus Technologies of Mexico, S.A. de C.V. (included as Exhibit 10.22 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
|
10.18
|
Stock Purchase Agreement, dated June 16, 2005, by and between Registrant, Quimica Pasteur, S de R.L., Francisco Javier Orozco Gutierrez and Jorge Paulino Hermosillo Martin (included as Exhibit 10.24 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
|
10.19
|
Framework Agreement, dated June 16, 2005, by and among Javier Orozco Gutierrez, Quimica Pasteur, S de R.L., Jorge Paulino Hermosillo Martin, Registrant and Oculus Technologies de Mexico, S.A. de C.V. (included as Exhibit 10.25 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
10.20
|
Mercantile Consignment Agreement, dated June 16, 2005, between Oculus Technologies de Mexico, S.A. de C.V., Quimica Pasteur, S de R.L. and Francisco Javier Orozco Gutierrez (included as Exhibit 10.26 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
|
10.21
|
Partnership Interest Purchase Option Agreement, dated June 16, 2005, by and between Registrant and Javier Orozco Gutierrez (included as Exhibit 10.27 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
|
10.22
|
Termination of Registrant and Oculus Technologies de Mexico, S.A. de C.V. Agreements with Quimica Pasteur, S de R.L. by Jorge Paulino Hermosillo Martin (translated from Spanish) (included as Exhibit 10.28 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
|
10.23
|
Termination of Registrant and Oculus Technologies de Mexico, S.A. de C.V. Agreements with Quimica Pasteur, S de R.L. by Francisco Javier Orozco Gutierrez (translated from Spanish) (included as Exhibit 10.29 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
|
10.24
|
Director Agreement, dated November 8, 2006, by and between Registrant and Robert Burlingame (included as Exhibit 10.34 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
|
10.25†
|
Exclusive Marketing Agreement, dated December 5, 2005, by and between Registrant and Alkem Laboratories Ltd (included as Exhibit 10.35 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
|
|
10.26
|
Securities Purchase Agreement, dated August 7, 2007, by and between Registrant and purchasers identified on the signatures pages thereto (included as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed August 13, 2007, and incorporated herein by reference).
|
|
10.27
|
Registration Rights Agreement, dated August 7, 2007, by and between Registrant and purchasers identified on signatures pages thereto (included as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed August 13, 2007, and incorporated herein by reference).
|
10.28
|
Form of Securities Purchase Agreement, dated March 27, 2008, by and between Registrant and each investor signatory thereto (included as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed March 28, 2008, and incorporated herein by reference).
|
|
10.29
|
Purchase Agreement by and between Registrant and Robert Burlingame, dated January 26, 2009 (included as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed January 29, 2009 and incorporated herein by reference).
|
10.30
|
Purchase Agreement by and between Registrant and Non-Affiliated Investors, dated January 26, 2009 (included as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed January 29, 2009 and incorporated herein by reference).
|
|
10.31
|
Revenue Sharing Distribution Agreement by and between Registrant and VetCure, Inc., dated January 26, 2009 (included as Exhibit 10.3 to the Company’s Current Report on Form 8-K filed January 29, 2009 and incorporated herein by reference).
|
|
10.32
|
Purchase Agreement by and between Registrant and accredited investors, dated February 6, 2009 (included as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed February 9, 2009 and incorporated herein by reference).
|
|
10.33
|
Purchase Agreement by and between Registrant, Robert Burlingame and Seamus Burlingame, dated February 24, 2009 (included as Exhibit 10.4 to the Company’s Current Report on Form 8-K filed February 27, 2009 and incorporated herein by reference).
|
|
10.34
|
Amendment to Revenue Sharing Distribution Agreement by and between Registrant and Vetericyn, Inc., dated February 24, 2009 (included as Exhibit 10.5 to the Company’s Current Report on Form 8-K filed February 27, 2009 and incorporated herein by reference).
|
|
10.35
|
Agreement by and between Registrant and Robert C. Burlingame, dated April 1, 2009 (included as Exhibit 10.52 to the Company’s Annual Report on Form 10-K filed on June 11, 2009 and incorporated herein by reference).
|
|
10.36
|
Microcyn U.S. Commercial Launch Agreement, by and between Registrant and Advocos, dated April 24, 2009 (included as Exhibit 10.53 to the Company’s Current Report on Form 10-K filed on June 11, 2009 and incorporated herein by reference).
|
|
10.37
|
Amendment No. 5 to Lease by and between Registrant and RNM Lakeville, LLC, dated May 18, 2009 (included as Exhibit 10.54 to the Company’s Current Report on Form 10-K filed on June 11, 2009 and incorporated herein by reference).
|
|
10.38
|
Engagement Agreement by and between Registrant and Dawson James Securities, Inc., dated April 10, 2009, (included as Exhibit 10.55 to the Company’s Registration Statement on Form S-1 (File No. 333-158539), as amended, declared effective on July 24, 2009, and incorporated herein by reference).
|
|
10.39
|
Letter Agreement by and between Registrant and Dawson James Securities, Inc., dated July 2, 2009, (included as Exhibit 10.56 to the Company’s Registration Statement on Form S-1 (File No. 333-158539), as amended, declared effective on July 24, 2009, and incorporated herein by reference).
|
|
10.40
|
Letter Agreement by and between Registrant and Dawson James Securities, Inc., dated July 10, 2009, (included as Exhibit 10.57 to the Company’s Registration Statement on Form S-1 (File No. 333-158539), as amended, declared effective on July 24, 2009, and incorporated herein by reference).
|
|
10.41
|
Warrant Purchase Agreement by and between Registrant and Dawson James Securities, Inc., dated July 13, 2009, (included as Exhibit 10.58 to the Company’s Registration Statement on Form S-1 (File No. 333-158539), as amended, declared effective on July 24, 2009, and incorporated herein by reference).
|
|
10.42
|
Loan and Security Agreement, dated May 1, 2010 between Oculus Innovative Sciences, Inc. and Venture Lending & Leasing V., Inc., (Included as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on May 6, 2010, and incorporated herein by reference).
|
|
10.43
|
Supplement to the Loan and Security Agreement, dated as of May 1, 2010 between Oculus Innovative Sciences, Inc., and Venture Lending & Leasing V, Inc., (included as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on May 6, 2010, and incorporated herein by reference).
|
|
10.44††
|
Amendment No. 3 to Revenue Sharing, Partnership and Distribution Agreement between the Registrant and Vetericyn, Inc. | |
31.1
|
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
31.2
|
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
32.1
|
Certification of Officers pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
†
|
Confidential treatment has been granted with respect to certain portions of this agreement.
|
††
|
Confidential treatment has been requested with respect to certain portions of this agreement.
|
Oculus Innovative Sciences, Inc.
|
||
Date: April 29, 2011
|
By:
|
/s/ Hojabr Alimi
|
Hojabr Alimi
|
||
|
Chairman of the Board of Directors and Chief
|
|
Executive Officer (Principal Executive Officer)
|
||
Date: April 29, 2011
|
By:
|
/s/ Robert Miller
|
Robert Miller
|
||
|
Chief Financial Officer
|
|
(Principal Financial Officer)
|
|
(c)
|
Section 3.3 Future Manufacturing Rights shall be amended in its entirety to read as follows:
|
|
(d)
|
Section 4.5 Branding of Solution shall be amended in its entirety to read as follows:
|
|
(e)
|
Section 5.1 Ownership of Company's IP shall not apply to the VETERICYN trademark as a result of the transfer of such trademark to Innovacyn, Inc. Furthermore, the following sentence shall be added to the end of Section 5.1: “Distributor shall have reasonable access to the Company’s IP as necessary to carry out its rights and obligations under this Agreement, but subject to the requirements of this Section 5 and Section 8.”
|
|
(f)
|
Section 9.2 Termination for Cause shall be amended in its entirety to read as follows:
|
OCULUS INNOVATIVE SCIENCES, INC.
|
|
By:
|
/s/ Jim Schutz |
Name:
|
Jim Schutz |
Title:
|
Chief Operating Officer |
VETERICYN, INC.
|
|
By:
|
/s/ Richard E. Jones |
Name:
|
Richard E. Jones |
Title:
|
Chief Financial Officer |
|
o
|
8 ounce trigger spray or 250 ml squeezable
|
|
§
|
Skin & Woundcare HydroGel, OTC
|
|
o
|
1.5
|
Year ending 2011:
|
$ [ ]*
|
|
Year ending 2012:
|
$ [ ]*
|
|
Year ending 2013:
|
$ [ ]*
|
|
Year ending 2014:
|
$ [ ]*
|
|
Year ending 2015:
|
$ [ ]*
|
|
Year ending 2016:
|
$ [ ]*
|
|
Year ending 2017:
|
$ [ ]*
|
|
Year ending 2018:
|
$ [ ]*
|
|
Year ending 2019:
|
$ [ ]*
|
|
Year ending 2020:
|
$ [ ]*
|
|
1.
|
If Cumulative Net Profit Before Revenue Sharing (“CNPBR”) is zero or negative, then Oculus Shared Revenue – Vetericyn (“OSRV”) is zero, or
|
|
2.
|
If Net Profit Before Revenue Sharing (“NPBR”) is zero or negative, then Oculus Shared Revenue – Vetericyn (“OSRV”) is zero, or
|
|
3.
|
If Oculus Shared Revenue – Vetericyn (“OSRV”) is greater than Cumulative Net Profit Before Revenue Sharing (“CNPBR”) for the month, then Oculus Shared Revenue – Vetericyn (“OSRV”) shall be equal to Cumulative Net Profit Before Revenue Sharing (“CNPBR”).
|
|
4.
|
For periods beginning after June 30, 2011, Oculus Shared Revenue – Vetericyn (“OSRV”) will be paid regardless of exceptions 1, 2 & 3 mentioned above.
|
|
1.
|
If Cumulative Net Profit Before Revenue Sharing (“CNPBR”) is zero or negative, then Oculus Shared Revenue – Puracyn (“OSRP”) is zero, or
|
|
2.
|
If Net Profit Before Revenue Sharing (“NPBR”) is [ ]*, then Oculus Shared Revenue – Puracyn (“OSRP”) is [ ]*, or
|
|
3.
|
If Oculus Shared Revenue – Puracyn (“OSRP”) is greater than Cumulative Net Profit Before Revenue Sharing (“CNPBR”) for the month, then Oculus Shared Revenue – Puracyn (“OSRP”) shall be equal to Cumulative Net Profit Before Revenue Sharing (“CNPBR”).
|
|
4.
|
For periods beginning after June 30, 2011, Oculus Shared Revenue – Puracyn (“OSRP”) will be paid regardless of exceptions 1, 2 & 3 mentioned above.
|
OCULUS INNOVATIVE SCIENCES, INC.
|
|
By:
|
/s/ Robert E. Miller |
Name:
|
Robert E. Miller |
Title:
|
Chief Financial Officer |
Date:
|
6/17/2010 |
VETERICYN, INC.
|
|
By:
|
/s/ Richard E. Jones |
Name:
|
Richard E. Jones |
Title:
|
Chief Financial Officer |
Date:
|
6/14/2010 |
INNOVACYN, INC.
|
|
By:
|
/s/ Richard E. Jones |
Name:
|
Richard E. Jones |
Title:
|
Chief Financial Officer |
Date:
|
6/14/2010 |
Registration
|
Fiscal Year
|
Fiscal Year
|
Fiscal Year
|
Fiscal Year
|
Fiscal Year
|
|||||||||||||||||
COUNTRY
|
Timeframe
|
3/31/2011
|
3/31/2012
|
3/31/2013
|
3/31/2014
|
3/31/2015
|
||||||||||||||||
JAPAN
|
12-18 months
|
$ | [ ]* | $ | [ ]* | $ | [ ]* | $ | [ ]* | |||||||||||||
KOREA
|
6-12 months
|
$ | [ ]* | $ | [ ]* | $ | [ ]* | $ | [ ]* | |||||||||||||
HONG KONG
|
None
|
$ | [ ]* | $ | [ ]* | $ | [ ]* | $ | [ ]* | $ | [ ]* | |||||||||||
CHINA
|
None
|
$ | [ ]* | $ | [ ]* | $ | [ ]* | $ | [ ]* | $ | [ ]* | |||||||||||
TAIWAN
|
None
|
$ | [ ]* | $ | [ ]* | $ | [ ]* | $ | [ ]* | $ | [ ]* | |||||||||||
SINGAPORE
|
None
|
$ | [ ]* | $ | [ ]* | $ | [ ]* | $ | [ ]* | $ | [ ]* | |||||||||||
MEXICO
|
None
|
$ | [ ]* | $ | [ ]* | $ | [ ]* | $ | [ ]* | $ | [ ]* | |||||||||||
Total
|
$ | [ ]* | $ | [ ]* | $ | [ ]* | $ | [ ]* | $ | [ ]* |
OCULUS INNOVATIVE SCIENCES, INC.
|
|
By:
|
/s/ Robert E. Miller |
Name:
|
Robert E. Miller |
Title:
|
Chief Financial Officer |
Date:
|
7/26/2010 |
VETERICYN, INC.
|
|
By:
|
/s/ Richard E. Jones |
Name:
|
Richard E. Jones |
Title:
|
Chief Financial Officer |
Date:
|
July 26,2010 |
INNOVACYN, INC.
|
|
By:
|
/s/ Seamus Burlingame |
Name:
|
Seamus Burlingame |
Title:
|
Executive Vice President |
Date:
|
7/26/10 |
By:
|
/s/ Hojabr Alimi
|
|
Date: April 29, 2011
|
Hojabr Alimi
|
|
Chief Executive Officer
|
By:
|
/s/ Robert Miller
|
|
Date: April 29, 2011
|
Robert Miller
|
|
Chief Financial Officer
|
Date: April 29, 2011
|
By:
|
/s/ Hojabr Alimi
|
Hojabr Alimi
|
||
Chief Executive Officer
|
||
Date: April 29, 2011
|
By:
|
/s/ Robert Miller
|
Robert Miller
|
||
Chief Financial Officer
|